Kelly Loeffler sold Allergan plc (AGN)
Kelly Loeffler (R-GA), a U.S. Senator, has disclosed 1 trade in Allergan plc (AGN) since 2020, a single sale, worth an estimated $375K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Kelly Loeffler sold $250,001 - $500,000 of Allergan plc (AGN) on April 14, 2020. Since that trade, AGN is down -42.30% against the S&P 500 up +179.63%, an outperformance of -221.93%.
Data updated
Kelly Loeffler's AGN trades vs the price
AGN is down -42.30% since Kelly Loeffler sold on April 14, 2020, versus +179.63% for the S&P 500.
Performance since this trade
All Kelly Loeffler AGN trades
Kelly Loeffler & AGN trading FAQ
Is it legal for Kelly Loeffler to trade Allergan plc (AGN) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Allergan plc (AGN), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Kelly Loeffler sell AGN?
Kelly Loeffler disclosed a sale of $250,001 - $500,000 of Allergan plc (AGN) on April 14, 2020, according to public STOCK Act filings.
How has AGN performed since Kelly Loeffler's trade?
Since Kelly Loeffler sold AGN on April 14, 2020, the stock is down -42.30%, versus +179.63% for the S&P 500 over the same period, an outperformance of -221.93%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional AGN trades?
Quantellect tracks every disclosed congressional trade in Allergan plc (AGN) on the Allergan plc congressional trading page, which aggregates filings across all members of Congress.
Kelly Loeffler's AGN tradesAll congressional filings for Allergan plcKelly Loeffler's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.